Cambridge, MA, Feb. 27, 2013 (GLOBE NEWSWIRE) -- LaVoie Strategic Communications Group, Inc. (LaVoie Group), a firm with a proven track record of building value for health science innovations through integrated communications and investor relations, congratulates the Commonwealth of Massachusetts and companies, patients and patient advocacy groups coming together February 28th for Rare Disease Day in an effort to raise awareness of rare and orphan diseases.
LaVoie Group, which is expert in orphan disease communications, is proud to be part of the effort to bring attention to the unique challenges presented by rare diseases and is committed to supporting communications programs through the various phases of development.
"We are proud of the events and efforts planned locally, nationally and around the world this week to bring attention to the researchers and developers of orphan disease solutions and the patients who need them," said Donna LaVoie, president and chief executive officer of LaVoie Group, who recently authored a white paper, Solving the Unique Problems of Orphan Drug Communications.
LaVoie Group and its executives have established expertise in orphan drug communications over a number of years, providing strategic communications counsel, including corporate communications, public relations and investor relations for numerous companies, including Aegerion Pharmaceuticals, Genzyme Corporation (now Sanofi), Pfizer, Inc. and Vertex Pharmaceuticals.
To download a free copy of the white paper, please visit: http://www.lavoiegroup.com/agency-news/white-paper-solving-the-unique-problems-of-orphan-drug-communications.html
LaVoie Group partners with its clients achieve their business goals by providing strategic consulting and integrated communications programs that properly position, engage target customers and stakeholders to create brand value. LaVoie Group is part of the IPREX network of global agencies.
Our clients are industry leaders in healthcare and government markets, including, Aegerion Pharmaceuticals, AliveCor, Vertex Pharmaceuticals, BIO, Radius Health, Haemonetics, Good Start Genetics, Novadaq Technologies, Rockwell Medical, the Commonwealth of Massachusetts, Hydra Biosciences and Xcovery Group of companies. LaVoie Group is part of INC. 500/500 private company list and is ranked by O'Dwyer's PR Report as one of the leading independent healthcare PR firms in the U.S. and has been honored for the past four years by the League of American Communications Professionals (LACP) for best agency awards, including the 2011 "Best Small Agency". The agency has been honored by sixteen awards in the last three years.